SEC Form 4 · accession 0001017491-16-000225
SEELOS THERAPEUTICS, INC. · SEEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kleanthis G Xanthopoulos
Director
Period of report
Sep 30, 2016
Accepted (ET)
Oct 3, 2016 · 4:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001017491
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 30, 2016 | A | 16,997 | $0.3383 | A | 95,746 | I | By Kleanthis and Gaylene Xanthopoulos TTEES, Xanthopoulos Family Trust Dtd 9/30/2011 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares of common stock were issued to the Reporting Person, a non-employee director of the Issuer, as partial payment for the quarterly retainer fee for his service as director of Issuer under an amended director compensation policy, which reduced the cash compensation payable to the Issuer's non-employee directors and in lieu of such cash compensation, resolved to grant shares of the Issuer's common stock.
- F2The value of the shares being delivered in satisfaction of the payment was calculated based on the closing price of the Issuer's common stock on September 30, 2016.